(Q34025199)

30 July 2017

1 reference

title

Clinical pharmacokinetics of cerivastatin (English)

1 reference

30 July 2017

1 reference

Mück W

1

1 reference

30 July 2017

1 August 2000

1 reference

Clinical Pharmacokinetics

30 July 2017

1 reference

30 July 2017

39

1 reference

30 July 2017

99-116

1 reference

30 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200039020-00002

30 July 2017

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

1 reference

12 December 2020

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

1 reference

12 December 2020

Influence of cholestyramine on the pharmacokinetics of cerivastatin.

1 reference

12 December 2020

Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers

1 reference

12 December 2020

Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells

1 reference

12 December 2020

Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.

1 reference

12 December 2020

Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1 reference

12 December 2020

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

12 December 2020

Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation

1 reference

12 December 2020

Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin

1 reference

12 December 2020

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

12 December 2020

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

12 December 2020

Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies

1 reference

12 December 2020

Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers

1 reference

12 December 2020

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1 reference

12 December 2020

Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-electrospray tandem mass spectrometry

1 reference

12 December 2020

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

12 December 2020

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia

1 reference

12 December 2020

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

1 reference

12 December 2020

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

1 reference

12 December 2020

Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition

1 reference

12 December 2020

Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: linking in vitro with in vivo information

1 reference

12 December 2020

Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved

1 reference

12 December 2020

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients

1 reference

12 December 2020

1 reference

12 December 2020

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

1 reference

12 December 2020

LC separation and induced fluorometric detection of rivastatin in blood plasma

1 reference

12 December 2020

Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor

1 reference

12 December 2020

Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia

1 reference

12 December 2020

The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man.

1 reference

12 December 2020

Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults

1 reference

12 December 2020

Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety

1 reference

12 December 2020

Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.

1 reference

12 December 2020

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Preclinical and clinical pharmacology of cerivastatin

1 reference

12 December 2020

Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor

1 reference

12 December 2020

Dual hepatic metabolism of cerivastatin--clarifications

1 reference

12 December 2020

Drug interactions of lipid-altering drugs

1 reference

12 December 2020

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor

1 reference

12 December 2020

Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.

1 reference

12 December 2020

No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin

1 reference

12 December 2020

Lack of drug-drug interaction between cerivastatin and nifedipine.

1 reference

12 December 2020

Effect of itraconazole on cerivastatin pharmacokinetics

1 reference

12 December 2020

Clinical pharmacokinetics of mibefradil

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance

1 reference

12 December 2020

Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin

1 reference

12 December 2020

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

1 reference

12 December 2020

Current and future treatment of hyperlipidemia: the role of statins

1 reference

12 December 2020

Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening.

1 reference

12 December 2020

Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

10.2165/00003088-200039020-00002

Identifiers

DOI

1 reference

PubMed ID

10976657

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

10976657